Publikace na 2. lékařská fakulta |
2015
Abstrakt
Philadelphia-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL) identifies an unfavorable subgroup of pediatric ALL characterized by the presence of the BCR-ABL1 chimeric protein. However, clinically Ph+ BCP-ALL remains a heterogeneous disease with an unfavorable response to therapy in a critical percentage of patients.
Even though introduction of tyrosine kinase inhibitors (TKIs) has improved outcome in pediatric PhMINUS SIGN BCP-ALL patients, 30% still relapse or die